๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 15 Guangzhou 13 Beijing 12 Harbin 5 Chongqing 4
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai15 Guangzhou13 Beijing12 Harbin5 Chongqing4
All 32 locations
Target enrolment
to

Trials with a site in Shanghai

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
NCT07283692Triple Negative Breast Cancer
RenJi Hospital
Phase 2
46
Shanghai
2026-03-01
Not yet open
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
NCT07419880Triple -Negative Breast Cancer
Fudan University
Phase 2
46
Shanghai
2026-01-30
Recruiting
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
NCT07705438Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
Fudan University
Observational
30
Shanghai
2025-05-28
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Active, closed
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370Triple Negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 3
350
Shanghai
2024-08-09
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
NCT06471205Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-08-02
Recruiting
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
160
Shanghai
2024-07-26
Recruiting
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
524
Shanghai
2024-02-28
Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060Triple-Negative Breast Cancer
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378Triple-Negative Breast Cancer
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682Triple-negative Breast Cancer
Fudan University
Phase 2
80
Shanghai
2022-06-30
Active, closed
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
NCT04296175Triple-negative Breast Cancer
Fudan University
Phase 3
808
Shanghai
2020-03-05
Active, closed
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
NCT02641847Triple Negative Breast Cancer, Breast Cancer
Fudan University
Phase 2/3
503
Shanghai
2016-01
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

10 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 15 studies
PhaseStudiesRecruitingShare
Phase 37446.7%
Phase 26540%
Observational116.7%
Phase 2/3106.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Fudan University85
Sichuan Baili Pharmaceutical Co., Ltd.21
Mabwell (Shanghai) Bioscience Co., Ltd.11
RenJi Hospital11
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.10
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.11
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.